Assobiotec

News

24 November 2020

Reithera announces its GRAd-COV2 COVID-19 vaccine candidate is well tolerated and induces clear immune responses in healthy subject aged 18-55 years phase 1 trial to advance into elderly subjects aged 65-85 years

ReiThera provides an update on the ongoing Phase 1 study of its vaccine candidate (GRAd-COV2) against the novel coronavirus (SARS-CoV-2)
  Read more
01 May 2020

CORONAVIRUS - Axxam supports drug discovery efforts to identify novel inhibitors for SARS-CoV-2

A commitment to support the identification of antiviral therapies to treat the severe acute respiratory syndrome COVID-19, caused by the Coronavirus SARS-CoV-2.
  Read more
23 March 2020

CORONAVIRUS - DiaSorin COVID-19 test has received FDA Emergency Use Authorization

DiaSorin Molecular LLC, a division of DiaSorin S.p.A. announced that it has received Emergency Use Authorization (EUA) from the FDA for their Simplexa™ COVID-19 Direct kit.
  Read more
21 March 2020

CORONAVIRUS - Takis announces that it is ready to test its Covid-19 vaccine on pre-clinical models

The authorization comes from the Ministry of Health and represents the first step in bringing the vaccine to human use. Takis researchers are the only ones in Italy and the first in Europe to access this phase of the experimentation.
  Read more
10 March 2020

CORONAVIRUS - DiaSorin has completed the studies to support the launch by the end of march 2020 of a rapid response molecular diagnostic test for the COVID-19

DiaSorin announced that it has completed at the Spallanzani Hospital in Rome and at the Policlinico San Matteo in Pavia, the studies necessary to support the CE marking and FDA EUA submission of an innovative molecular test for the rapid identification of the novel coronavirus COVID-19.
  Read more
03 March 2020

CORONAVIRUS - Applied DNA Sciences updates on COVID-19 collaboration with Takis Biotech, 4 Preclinical LinearDNA™ Vaccine candidates designed

Applied DNA Sciences Inc. and Takis Biotech announced that the design of 4 DNA vaccine candidates that will be produced for preclinical animal testing via the Company’s proprietary PCR-based DNA manufacturing systems
  Read more
1 2 

Where to find us

20149 Milan
Via Giovanni da Procida, 11
Show map 
Tel. +39 02.34565.1
Fax. +39 02.34565.310
Segreteria Assobiotec
Tel. 02 34565.256/341
assobiotec@federchimica.it